Bare necessities? The utility of full skin examination in the COVID-19 era

C. O’Connor,1,2 C. Gallagher,1 M. O’Connell,1 J. Bourke,1,2 M. Murphy1,2 and M. Bennett1
1Department of Dermatology, South Infirmary Victoria University Hospital, Cork, Ireland; and 2Department of Medicine, University College Cork, Cork, Ireland
doi:10.1111/ced.14620

Summary

Full skin examination (FSE) may improve the detection of malignant melanoma (MM). The objective of this study was to assess the safety of targeted lesion examination (TLE) compared with FSE in our Pigmented Lesion Clinic (PLC). Patients attending the PLC were randomized in a 2 : 1 ratio to FSE (intervention) or TLE (standard care). Demographic details and risk factors were documented, and the time taken to perform FSE and TLE was noted. Of 763 participants, 520 were assigned to FSE and 243 were assigned to TLE. On average, FSE took 4.02 min and TLE took 30 s to perform. Of the 520 participants assigned to FSE, 37 (7.1%) had incidental findings, of whom 12 patients (2.3%) had additional lesions biopsied. No additional melanomas were detected that would have been missed by use of the standard protocol. This study suggests that in low-risk patients referred to a PLC with a lesion of concern, the possibility of missing incidental cutaneous malignancies using lesion-directed examination is low.

Full skin examination (FSE) may help in the early detection of malignant melanoma (MM).1 However, the US Preventative Services Task Force does not recommend routine FSE, citing a lack of evidence for its efficacy in reducing mortality.2 Hartman et al. recently highlighted the economic and time limitations in routinely performing FSE.3 The monumental impact of the COVID-19 pandemic has increased pressure on dermatology resources, and patient exposure to unnecessary healthcare interventions should be minimized.4

The Pigmented Lesion Clinic (PLC) at our centre accepts referrals from general practitioners (GPs) for patients with a suspicious pigmented lesion(s). The lesion(s) in question is examined by a consultant dermatologist. Any other lesion of concern to the patient is also examined. FSE is performed only in patients with a prior personal or family history of MM and in male patients aged > 50 years, as these patients are considered to be at higher risk of MM. Patients who have a suspicious lesion biopsied also undergo FSE.

The aim of this study was to assess the safety of targeted lesion examination (TLE) compared with FSE, and to determine the types of lesions that were likely to be missed if only TLE, and not FSE, was performed.

Report

Ethics approval was provided by the Clinical Research and Ethics Committee of the Cork Teaching Hospitals. Patients attending 34 PLCs over a 20-month period were invited to participate in the study, and written informed consent was obtained.

Patients were randomized in a 2 : 1 ratio to either FSE (intervention group) or TLE (standard of care). Male patients aged > 50 years and patients with a personal or family history of MM were assigned to FSE as per departmental protocol. Those selected to undergo FSE had the additional examination performed by a senior dermatology specialist registrar.
following their standard assessment (TLE) by a consultant dermatologist. Those randomly selected to undergo TLE had the examination performed by a consultant dermatologist as part of the standard assessment.

Demographic details recorded included age, sex, personal or family history of MM, prior sunbed use, average number of sun holidays per year, prolonged periods spent abroad and occupation (indoor, outdoor or mixed). The length of the examination was timed for both FSE and TLE, and details of additional identified lesions were recorded. A biopsy was taken from any patients in whom additional suspicious lesions were identified.

In total, 766 patients consented to participate; 523 of these patients were assigned to FSE and 243 were assigned to TLE. Three patients declined FSE, citing reasons such as time pressure, embarrassment, and menstruation, resulting in a final group size of 520 for FSE. No patient declined TLE. Most participants were white Irish, female, middle-aged and worked indoors; 1.3% had a previous history of MM, 7.9% had a family history of MM and 25.6% had previously used sunbeds (Table 1).

On average, FSE took 4.02 min to perform, from asking the patient to undress to the patient being fully dressed following the examination. By contrast, the average TLE took 30 s, therefore FSE took eight times longer than TLE. FSE took slightly longer (5.6 min) in male patients aged >60 years, whereas the duration of TLE was not dependent on age or sex.

Of the 520 patients assigned to FSE, 37 (7.1%) had incidental findings on FSE, including inflammatory dermatoses such as psoriasis and eczema, and previously undiagnosed porphyria cutanea tarda (Table 2). Twelve patients (2.3%) had additional lesions biopsied, including a superficial basal cell carcinoma. No additional MMs were detected by FSE that would otherwise have been missed by use of the standard protocol (TLE).

This study suggests that in low-risk patients referred to a PLC with a lesion of concern, the possibility of missing incidental cutaneous malignancies using lesion-directed examination is low, and that TLE is a safe and efficient practice in this setting. A previous study has shown that most MMs are picked up in patients referred with a lesion rather than during routine mole checks. Patients attending our PLC have already been reviewed by their GP and therefore any lesions of concern may have already been identified by FSE in primary care. Dermatologists have also reported patient embarrassment and time constraints as significant barriers to skin cancer screening using FSE. In this study, at the time of randomization, three patients declined participation in FSE, but none declined participation in TLE, suggesting that patient satisfaction with TLE is high.

There may be limitations to extrapolating these data to other regions with higher prevalences of MM, such

Table 1 Patient demographics with details on melanoma history and sun exposure.

| Full skin examination (n = 520) | Result |
|-------------------------------|--------|
| **Demographics**              |        |
| Female sex, n (%)             | 372 (71.5) |
| Average age, years            | 44.9 |
| White Irish, n (%)            | 479 (92.1) |
| **MM history, n (%)**         |        |
| Personal history of MM        | 7 (1.3) |
| First-degree relative with MM | 24 (4.6) |
| Second-degree relative with MM| 17 (3.3) |
| Two or more relatives with MM | 4 (0.8) |
| **Sun exposure history, n (%)**|        |
| Indoor occupation             | 405 (77.9) |
| Outdoor or mixed occupation   | 115 (22.1) |
| Previous sunbed use           | 133 (25.6) |
| Previous phototherapy         | 1 (0.2) |
| Migration > 12 months outside Ireland | 85 (16.3) |

MM, malignant melanoma.

Table 2 Additional clinical or histological diagnoses detected on full skin examination that would not have been detected with targeted lesional examination, excluding seborrhoeic keratosis, actinic keratosis, lentigines, viral warts, angiomata, acne, folliculitis and keratosis pilaris.

| Diagnoses                                           | n (%)  |
|-----------------------------------------------------|--------|
| **Clinical diagnosis**                              |        |
| Dermatofibroma                                       | 10 (1.9)|
| Psoriasis                                            | 6 (1.2)|
| Dermatitis                                           | 4 (0.8)|
| Naevus spilus                                        | 4 (0.8)|
| Linear epidermal naevus                              | 2 (0.4)|
| Porphyria cutanea tarda                              | 2a (0.4)|
| Pigmented purpuric dermatosis                        | 2 (0.4)|
| Halo naevus                                          | 1 (0.2)|
| Becker naevus                                        | 1 (0.2)|
| Lichen simplex chronicus                             | 1 (0.2)|
| Hidradenitis suppurativa                              | 1 (0.2)|
| Port wine stain                                      | 1 (0.2)|
| Erythema ab igne                                     | 1 (0.2)|
| Varicose ulcer                                       | 1 (0.2)|
| **Histological diagnosis**                           |        |
| Dysplastic naevus with mild atypia                   | 10 (1.9)|
| Blue naevus                                          | 1 (0.2)|
| Basal cell carcinoma, superficial                     | 1 (0.2)|

*aOnly one attended for confirmatory biochemical diagnosis.*
as Australia and New Zealand. One Australian study showed a high rate of MM detected incidentally by FSE in private practice, mostly in men, with a mean age of 61.9 years. Dermatology training may also be affected if TLE is adopted over FSE, as trainees may have less experience in assessing benign or low-risk lesions such as seborrhoeic keratoses, angiomas or benign melanocytic naevi.

Access to specialist dermatologist services is limited, particularly in the COVID-19 era. This study shows that FSE takes eight times longer than TLE. Although FSE is superior to TLE if resources are unlimited, FSE has minimal benefit in detecting additional skin cancers and TLE permits more patients to be seen in our restricted face-to-face (F2F) clinic appointments. Therefore, we suggest that TLE should be adopted as the standard of care for low-risk patients in PLC in order to optimize efficiency in the COVID-19 era.

**Learning points**
- FSE may help in the early detection of MM; however, FSE may not reduce mortality, and has economic and time limitations.
- The COVID-19 pandemic has increased pressure on dermatology resources, and patient exposure to unnecessary healthcare interventions should be minimized.
- This study suggests that in low-risk patients attending a PLC referred with a lesion of concern, the possibility of missing incidental cutaneous malignancies using TLE is low.
- Although FSE is superior to TLE if resources are unlimited, FSE has minimal benefit in detecting additional skin cancers, and TLE permits more patients to be seen in our restricted F2F clinic appointments.

**References**
1. Chiaravalloti AJ, Laduca JR. Melanoma screening by means of complete skin exams for all patients in a dermatology practice reduces the thickness of primary melanomas at diagnosis. *J Clin Aesthet Dermatol* 2014; 7: 18–22.
2. US Preventive Services Task Force. Screening for skin cancer: US Preventive Services Task Force recommendation statement. *JAMA* 2016; 316: 429–35.
3. Hartman RI, Xue Y, Singer S et al. Modeling the value of risk stratified skin cancer screening of asymptomatic patients by dermatologists. *Br J Dermatol* 2019; 183: 509–15.
4. British Association of Dermatologists. COVID-19: clinical guidelines for the management of dermatology patients remotely. 2020. Available at https://www.bad.org.uk/healthcare-professionals/covid-19/remote-dermatology-guidance (accessed 12 November 2020).
5. Carli P, De Giorgi V, Palli D et al. Dermatologist detection and skin self-examination are associated with thinner melanomas results from a survey of the Italian Multidisciplinary Group on Melanoma. *Arch Dermatol* 2003; 139: 607–12.
6. Oliveria SA, Heneghan MK, Cushman LF et al. Skin cancer screening by dermatologists, family practitioners, and internists barriers and facilitating factors. *Arch Dermatol* 2011; 147: 39–44.
7. Cherian P, Tait CP. Melanoma in private practice: do dermatologists make a difference? *Australas J Dermatol* 2009; 50: 257–60.
8. Zalaudek I, Kittler H, Marghoob AA et al. Time required for a complete skin examination with and without dermoscopy. a prospective, randomized multicenter study. *Arch Dermatol* 2008; 144: 509–13.